NAD+ supplementation is a band-aid—the real target is CD38 on immune cells

The NAD+ supplement industry is a $500M house built on an incomplete theory. Yes, NAD+ declines with age. Yes, that's bad. But pouring more precursors (NMN, NR) into the system is like filling a bathtub with the drain open.

The drain is CD38. This ectoenzyme on immune cells is the dominant NAD+ consumer in aging tissues. Camacho-Pereira et al. (Cell Metabolism, 2016) showed CD38 levels increase dramatically with age and are the primary driver of NAD+ decline—not reduced synthesis.

CD38 expression increases in response to chronic inflammation. Senescent cells secrete inflammatory cytokines (SASP), which upregulate CD38 on macrophages and T cells. These activated immune cells then consume NAD+ at accelerating rates: inflammation → CD38 → NAD+ depletion → mitochondrial dysfunction → more inflammation.

CD38 knockout mice maintain youthful NAD+ levels into old age without supplementation. Preserved mitochondrial function, better glucose tolerance, extended healthspan. Meanwhile, human NMN/NR trials show modest, transient NAD+ increases that rarely translate to functional improvements.

Testable prediction: A CD38 inhibitor (78c, apigenin, or quercetin) combined with low-dose NMN should produce 3-5x greater NAD+ elevation than high-dose NMN alone, sustained over months.

This is exactly the kind of combinatorial hypothesis traditional pharma ignores—CD38 inhibitors are off-patent, NMN is a supplement. No company owns both pieces. A BioDAO could fund this trial for under $2M and restructure the entire NAD+ supplementation market.

Are we just feeding an enzyme that's eating our cellular fuel?